Wed, Jul 30, 2014, 2:46 PM EDT - U.S. Markets close in 1 hr 14 mins

Recent

% | $
Click the to save as a favorite.

Sarepta Therapeutics, Inc. Message Board

faosto 259 posts  |  Last Activity: Jul 28, 2014 4:11 PM Member since: Dec 10, 1997
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • faosto faosto Jul 28, 2014 4:11 PM Flag

    hey callstothewall, where's my buyout!!!!???? ;-)

  • faosto faosto Jul 23, 2014 11:46 PM Flag

    16,700 shares treaded at around $46 a share - $770,000 in value was sold and $670 mill in market cap shaved, over a trial that has no bearing on the drug's approval. Amazing. The control arm had a six fold better than normal efficacy, which is why ICY's drug didn't reach statistical significance. I think once they dig into the data, they'll figure out why. In the meantime, it doesn't matter!

  • Reply to

    Is anyone adding to their position in after hours?

    by md4brain Jul 23, 2014 6:23 PM
    faosto faosto Jul 23, 2014 6:29 PM Flag

    My take on the AH action is not about Sovaldi - it's about Idelalisib (Zydelig). The box warning and the need for a REMS (for now), coupled with the fact that between this drug and Rituxan (approved taken together) it's $4000 more than Imbruvica, may really blunt sales of the drug in the short term. The company, however, is still way undervalued, regardless. They will hyit at least $8 EPS this year, and at 15X that's a $120 stock. That's a 33% upside at least!

  • Reply to

    Glaxo reported to be mulling takeover.

    by bearofbleecker Jul 22, 2014 1:13 PM
    faosto faosto Jul 22, 2014 5:21 PM Flag

    what do you think is a fair price for ITMN? I'd say around $72-75.

  • Reply to

    Needham downgrades to hold....

    by snosurfer08012 Jul 22, 2014 1:53 PM
    faosto faosto Jul 22, 2014 5:14 PM Flag

    I just read the transcript. Worse than I thought. The big design loss is unfortunate, and it appears it's with their 30% customer. Their low-end guidance is horrible - an average of 15.5 million per quarter in second half. (They have already produced $37 mill, and the range is now $68 mill-72 mill). EPS will be lucky to hit $2, with last year at $2.45. My new entry point: $20-$22.

  • Reply to

    Needham downgrades to hold....

    by snosurfer08012 Jul 22, 2014 1:53 PM
    faosto faosto Jul 22, 2014 3:10 PM Flag

    Analysts aside, I lost faith at 5:10 a.m. west coast time and bailed pre-market at $35. The CEO is a masterful promoter. It's curious to me how little momentum the company has had in the past 6 months. I guess this is the downside of promoting every design win, and every product line extension. Now he says the market is soft, but I didn't see any appreciable softness in NTAP's first quarter earnings report - one of SILC's major customers. My take is that the business SILC is in is cutthroat with razor thin margins, but that SILC's innovation is what has propelled them forward. I suspect it isn't too difficult to reverse engineer bypass switches, adapters, etc., and that their innovation lead can be marginalized quickly. Nearly every quarter for the past two years, the CEO has announced a design win. We've hit a dry spell, and growth rates are down. Whether this is symptomatic of a far bigger problem has yet to be seen, but since I bought back in close to $50, I allowed this to bleed way too long. Good luck to those who hold. I won't be back in unless the momentum comes back. I've been in and out of this stock since it was $7 a share, but this last round took most of my profits from the past on this stock. Shame on me for a very bad trade!

  • Reply to

    Earning Date??

    by xbruinboyx Jul 21, 2014 1:21 PM
    faosto faosto Jul 21, 2014 4:04 PM Flag

    Yahoo is showing it as today in their earnings calendar

  • Reply to

    Am I in a timewarp?

    by bearofbleecker Jul 19, 2014 3:29 PM
    faosto faosto Jul 20, 2014 2:44 PM Flag

    The news broke Thursday. But let's do a reality check on the situation. The day before, Boehringer Ingelheim received Breakthrough designation for Nintedanib, ITMN's competitor. The only reason of course that both drugs are getting this designation is not because of efficacy, but because no drug exists on the US market today that specifically treats IPF. However, the publically available surveys of docs suggest that ITMN's drug perfenidone will be prescribed first in at least 75% of cases. Secondly, most IPF patients will probably cycle through both drugs, as their effectiveness tends to lessen over time. But, going back to the application process - ITMN is in a re-submission situation, with a six month review to begin with, which originally put their drug at a late November PDUFA. BI's drug is a first application, which will push then into next year. and with breakthrough, I've stated before that I think this will shave 2-3 months off the approval process for ITMN, putting a possible approval as early as late August or September. We'll see!

    Sentiment: Strong Buy

  • Reply to

    Shire call

    by fatty_mcknuckles Jul 18, 2014 9:42 AM
    faosto faosto Jul 18, 2014 6:38 PM Flag

    I'm actually not negative on npsp - I'm looking for solid reasons to get back in, and if there's an article out there that details what this new division is able to do (i.e. make their own acquisitions), then I'm all eyes. Odds are close to 100% that I will be back in before Natpara's approvbal, which is imminent. Still not sure how this quarter will look given last qtr, that's all.

  • Reply to

    Shire call

    by fatty_mcknuckles Jul 18, 2014 9:42 AM
    faosto faosto Jul 18, 2014 4:02 PM Flag

    where did you find the part about the new unit being able to make its own acquisitions?

  • Reply to

    Shire call

    by fatty_mcknuckles Jul 18, 2014 9:42 AM
    faosto faosto Jul 18, 2014 3:53 PM Flag

    fatty, do you have a link to this? I've found the first part of the statement, but I can't find anywhere that says the new unit will have capital to pursue deals.

  • Reply to

    Where is everyone??

    by ajdoha234 Jul 14, 2014 1:08 PM
    faosto faosto Jul 17, 2014 8:36 PM Flag

    I think ITMN will be acquired after approval, but the curve ball that may happen now with breakthrough designation on a re-submission means this could get approval in late August or in September, and it will surprise the market quite a bit.

  • That's great news! This will speed up approval and willl also generate more interest in a buyout!

  • faosto faosto Jul 17, 2014 4:18 PM Flag

    This is going down right now for two reasons: first is obviously the overall biotech and market selloffs due to Yellen, Israel, Russia. Malasian Airlines, etc. The second reason is that according to the NYTimes, the deal to buyout Shire will be announced in the morning - I suspect before market open , but definitely before market close. Tomorrow is the deadline placed on Shire and Abbvie to cut a deal or walk for six months. With this deal it is unlikely that NPSP will be bought out by the combined entity anytime soon. I'm now staying out until before the Natpara approval.

    Sentiment: Sell

  • Reply to

    So is Yellen going to tell everyone when she thinks

    by mjjk1 Jul 15, 2014 2:07 PM
    faosto faosto Jul 15, 2014 11:11 PM Flag

    I just learned that Fed Reserve bnoard members are allowed to trade stocks while in their position. Yellen probably had a short on the biotech index yesterday, prior to this morning's comment!

  • Reply to

    You may not like Cramer ...

    by fishart4 Jul 15, 2014 6:21 PM
    faosto faosto Jul 15, 2014 10:12 PM Flag

    Actually I like Cramer. He makes several wrong calls, but who doesn't? Overall he's smart, instinctive, and has an impressive base of knowledge across all sectors of the market. Take him for what he is: a highly opinionated guy whose opinions often are on the mark.

  • Reply to

    So is Yellen going to tell everyone when she thinks

    by mjjk1 Jul 15, 2014 2:07 PM
    faosto faosto Jul 15, 2014 4:12 PM Flag

    What place does the fed chairman have commenting on stock valuations? Those valuations are determined by market forces and have no business in her realm of commentary. Is she going to start commenting on each and every sector of the market? Oil stocks are really high this month? The utilities are now overpriced? Bonds are fundamentally undervalued? he fed is supposed to ensure a stable economy, and economists are supposed to "get" that the stock market goes through a series of healthy corrections all by itself - to cause an artificial one is out of bounds and someone in congress or the president ought to let her know.

  • Reply to

    August 6, 2014

    by faosto Jul 9, 2014 7:15 PM
    faosto faosto Jul 15, 2014 3:59 AM Flag

    If you want a quick trade, sell pcyc on August 5 in the morning, and then buy it back on Aug 6 at around 11-noon on the 6th after Idelalisib is approved.

  • Reply to

    Shire wont happen soon....

    by showman01 Jun 29, 2014 10:43 AM
    faosto faosto Jul 15, 2014 3:43 AM Flag

    I think Shire/Abbvie will be announced tomorrow or Wednesday at the latest - the deadline is the 18th. Shire is as good as gone; NPSP unfortunately will fall I think to $26. I posted that I got out of NPSP after the last quarter due to a slower than expected start on Gattex. They adjusted their annual sales downward from 110-120 to 100-110, and their Gattex revs only went up 2.5 mill from the previous quarter. I'm telling you this as a former long that had NPSP as my largest position (now its ITMN): I think NPSP is headed for $20 before Natpara gets approved. Then back up to $30+. Shower me with 10 thumbs down, but just know this: I never short. I'm just watching NPSP like a hawk right now.

  • faosto faosto Jul 11, 2014 3:09 PM Flag

    If senators are going to get into the drug business then they had better educate themselves on the macro view of healthcare costs per disease. Traditional hep c treatments have a 50% cure rate at best, and up to 20% of chronic carriers develop cirrhosis. Liver transplants are $550,000 each. One liver transplant = 6-7 cured individuals. And if they believe in letting the market work this out, then they should do nothing. Once a couple more treatments are approved, there will be a price squeeze, but Gilead will still do fine.

SRPT
22.96+2.63(+12.94%)2:45 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.